Effectiveness of chronic hepatitis C treatment with direct-acting antivirals in the Public Health System in Brazil
Open Access
- 21 July 2018
- journal article
- research article
- Published by Elsevier BV in The Brazilian Journal of Infectious Diseases
- Vol. 22 (4), 317-322
- https://doi.org/10.1016/j.bjid.2018.06.004
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Current and future HCV therapy: do we still need other anti‐HCV drugs?Liver International, 2014
- Global epidemiology and genotype distribution of the hepatitis C virus infectionJournal of Hepatology, 2014
- Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised studyThe Lancet, 2014
- Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3The New England Journal of Medicine, 2014
- The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigmJournal of Viral Hepatitis, 2014
- Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV InfectionThe New England Journal of Medicine, 2014
- HCV direct‐acting antiviral agents: the best interferon‐free combinationsLiver International, 2013
- Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment OptionsThe New England Journal of Medicine, 2013
- Prevalence and risk factors of Hepatitis C virus infection in Brazil, 2005 through 2009: a cross-sectional studyBMC Infectious Diseases, 2013
- Production of infectious hepatitis C virus in tissue culture from a cloned viral genomeNature Medicine, 2005